SCHEMBL5537048

SCHEMBL5537048

O=C(c1cc(-c2c(Cl)cccc2Cl)c[nH]1)c1cccnc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RORB Q92753 1/20 0.41
ALDH1A1 P00352 3/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
PKM P14618 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
GFER P55789 1/20 0.39
CCNC P24863 2/20 0.39
CDK8 P49336 2/20 0.39
POLB P06746 1/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537750 0.76 SMN1; SMN2 (0.46) LMNASMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL5535242 0.76 SMN1; SMN2 (0.46) LMNASMN1; SMN2ALDH1A1L3MBTL1GFER
SCHEMBL5533787 0.75 POLB (0.53) ALDH1A1L3MBTL1PKMTDP1POLB
SCHEMBL21802604 0.73 MAP2K1 (0.45) LMNASMN1; SMN2ALDH1A1POLBMTNR1A
SCHEMBL5542413 0.73 SMN1; SMN2 (0.45) LMNASMN1; SMN2RORBL3MBTL1CASP3
SCHEMBL22044890 0.72 LMNA (0.42) LMNASMN1; SMN2ALDH1A1L3MBTL1PKM
SCHEMBL5534265 0.72 SMN1; SMN2 (0.54) LMNASMN1; SMN2L3MBTL1CASP3SENP8
SCHEMBL29565508 0.72 SMN1; SMN2 (0.54) LMNASMN1; SMN2L3MBTL1CASP3SENP8
SCHEMBL950218 0.72 LMNA (0.73) LMNASMN1; SMN2ALDH1A1L3MBTL1CASP3
SCHEMBL5543840 0.71 LMNA (0.46) LMNASMN1; SMN2ALDH1A1L3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186716-B2 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors SUGEN, INC. (US) 2007-03-06 US disclosed
EP-1545515-A1 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS Sugen, Inc. (US) 2005-06-29 EP disclosed
US-20040092546-A1 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors SUGEN, INC. 2004-05-13 US disclosed
WO-2004014368-A1 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS SUGEN, INC. (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092546-A1 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors MAP3K19, MAP3K1, MAP3K7 LMNA 3281/4885SMN1; SMN2 3900/4885RORB 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.